Detalhe da pesquisa
1.
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Invest New Drugs
; 36(5): 848-859, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29349598
2.
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Clin Cancer Res
; 30(8): 1630-1641, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319672
3.
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.
ESMO Open
; 4(4): e000532, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31423336
4.
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
Cancer Chemother Pharmacol
; 82(3): 395-406, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29915982
5.
Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.
Mol Cancer Ther
; 17(7): 1464-1474, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29654069
6.
Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab.
Cancer Chemother Pharmacol
; 79(6): 1239-1247, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28497320
7.
89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.
Clin Cancer Res
; 23(20): 6128-6137, 2017 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28733442
8.
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
Clin Cancer Res
; 23(18): 5406-5415, 2017 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28600476
9.
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
Clin Cancer Res
; 22(4): 877-85, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26463709
10.
Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide.
FASEB J
; 16(8): 860-2, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-11967228
11.
Converting a peptide into a drug: strategies to improve stability and bioavailability.
Curr Med Chem
; 9(9): 963-78, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-11966456
12.
A 13 kDa carboxy-terminal fragment of ApoE stabilizes Abeta hexamers.
J Neurochem
; 94(5): 1351-60, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16011742
13.
Passage of murine scrapie prion protein across the mouse vascular blood-brain barrier.
Biochem Biophys Res Commun
; 318(1): 125-30, 2004 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-15110762
14.
Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease.
J Biol Chem
; 278(16): 13905-11, 2003 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-12578830